Thierry Bussiere

Company: Biogen

Job title: Scientific Director Neurodegenerative Diseases Research Unit

Seminars:

Panel Discussion: Is Plaque Reduction a Valid Marker of Response & Sufficiently Relevant to Drug Efficacy? 9:00 am

Navigating how the recent approval of amyloid clearing antibody drugs will affect regulator perception of plaque reduction as a marker of drug efficacy Reviewing if plaque targeting is relevant for drugs with a different mechanism of action and if this affects the safety profile too significantly Exploring the relevance of plaque clearance in heterogenous pathology…Read more

day: Conference Day One

Developing a Reliable Mouse Model to Better Understand and Predict ARIA-E and ARIA-H Observed in Subjects Treated with Anti-Aβ Immunotherapy: Myth or Reality? 8:00 am

Risk factors for the occurrence of ARIA in patients treated with Abeta immunotherapy are being elucidated, but pathogenic mechanisms involved in ARIA remain hypothetical Deciphering these pathogenic mechanisms, or defining features of new molecules that would prevent the occurrence of ARIA remain a priority for the field Basic research effort is needed to develop reliable…Read more

day: Conference Day One